Research programme: bifunctional short hairpin cancer therapeutics - Gradalis/Mary Crowley Research CenterAlternative Names: pbi-shPDX-1 LP; pbi-shRNA K-ras LP
Latest Information Update: 06 Mar 2012
At a glance
- Originator Gradalis; Mary Crowley Cancer Research Center
- Class Lipids; Small interfering RNA
- Mechanism of Action Pancreatic and duodenal homeobox 1 protein inhibitors; RNA interference; Stathmin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Mar 2012 Preclinical development is ongoing in USA